Reports

Drug name	NICE TAs	Comments
Gemtuzumab ozogamicin	TA545 - Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
Glatiramer acetate (Copaxone®)	TA527 - Beta interferons and glatiramer acetate for treating multiple sclerosis
Glatiramer injection	TA254 - Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis TA527 - Beta interferons and glatiramer acetate for treating multiple sclerosis
Gliteritinib	TA642 - Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
Golimumab injection	TA233 - Golimumab for the treatment of ankylosing spondylitis TA220 - Golimumab for the treatment of psoriatic arthritis TA225 - Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs	Hospital use only
Guselkumab	TA711 - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs
Guselkumab (Tremfya®)	NICE TA 1094 Guselkumab for treating moderately to severely active ulcerative colitis NICE TA 1095 Guselkumab for previously treated moderately to severely active Crohn's disease	Please contact mmag@uhb.nhs.uk for advice
Hydrocortisone 0.5% cream	TA81 - Frequency of application of topical corticosteroids for atopic eczema	Mild potency
Hydrocortisone 0.5% ointment	TA81 - Frequency of application of topical corticosteroids for atopic eczema	Mild potency
Hydrocortisone 1% cream	TA81 - Frequency of application of topical corticosteroids for atopic eczema	Mild potency

University Hospitals Birmingham NHS Foundation Trust